Article Details

Gilead, MacroGenics Unite Against Hematologic Cancers in $1.7B Biobuck Deal

Retrieved on: 2022-10-17 20:05:32

Tags for this article:

Click the tags to see associated articles and topics

Gilead, MacroGenics Unite Against Hematologic Cancers in $1.7B Biobuck Deal. View article details on hiswai:

Excerpt

The asset was developed using MacroGenics' DART technology platform. ... MacroGenics has two distinct technology platforms: DART and TRIDENT.

Article found on: www.pharmalive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up